Manufacturing — Biologicals Manufacturing

2-year Backlog in Biologicals Manufacturing Hinders Medical R&D, Development of New Therapies for COVID-19 A shortage of Contract Development and Manufacturing Organizations (CDMOs) has put a severe strain on treating COVID and other post-viral syndromes; especially for products developed for regenerative medicine. Dr. Ian White, President and CSO of Neobiosis, explains how this shortage has caused a 2-year backlog on desperately needed medical technologies. The demand for biologicals skyrocketed so quickly that supply has not been able to keep pace. There is a gap between research and manufacturing that has been highlighted by COVID-19. America is in desperate need of...